Program

September 28, 2016
7:30 AM	Registration – Lobby
7:45 AM	Breakfast – The Pechet Room
8:45 AM	Welcome Remarks – Amphitheatre
9:00 AM – 10:20 AM	WHY ASIA? – Understanding the opportunities for partnering and financing in the Asian markets including the epidemiology of Asia William Cacheris, President, Tessellon Inc. Chris Francis, PhD, Senior Vice President, Corporate Development & Portfolio Management, WAVE Life Sciences Matt Heimerdinger, Research Director, Anterio Inc. James B. Weissman, CBO, Dicerna Pharmaceuticals Nat Whitney, President, Whitney Research
10:20 AM – 10:35 AM	Break
10:35 AM – 11:25 AM	BUILDING YOUR ASIAN IQ – The key issues to understand and the steps to take in Asia Larry Cai, Head of Business Development, New England, Qilu Pharmaceuticals Sara Jane Demy, Founder & CEO, Demy-Colton James Foley, PhD, Managing Director, Aqua Partners LLC Charles Hsu, PhD, Managing Partner, Crosswave Management
11:30 AM – 12:25 PM	FOCUS ON SIMILARITIES AND DIFFERENCES – Parsing the myths, true and untrue, about China, Korea and Japan James Foley, PhD, Managing Director, Aqua Partners LLC Charles Hsu, PhD, Managing Partner, Crosswave Management Alan Seem, Partner, Shearman & Sterling LLP Jeff Tomlinson, CBO, ASLAN Pharmaceuticals
12:30 PM – 1:40 PM	Lunch with the Experts
1:45 PM – 2:40 PM	MONEY IN ASIA – Investing in biotech companies in Asia and North America David H. Deming, Managing Partner, TAG Healthcare Advisors Wenseng Wendy Pan, PhD, Partner, Sidley Austin LLP Mark Tang, Managing Director, Good Health Capital Jimmy Zhang, PhD, Managing Director, Cross-Border Investment, CL Investment Group
2:40 PM – 2:55 PM	Break
2:55 PM – 3:40 PM	CLINICAL TRIAL DESIGN IN ASIA – Collaborating with CROs and CMOs on where you run your study and where you manufacture Pey Ni Chan, Managing Director, CMIC Asia-Pacific, Pte. Ltd. RuiPing Dong, Managing Director, RuiPing Consulting Keiko Oishi, Senior Managing Director, CMIC Co., Ltd Gunther Winkler, Co-Founder and CEO, Biometheus LLC
3:45 PM – 4:55 PM	THE DEAL LANDSCAPE – An inside look at the cross-border deals including successful deals, unsuccessful deals and breakthrough deals Sean Cao, PhD, Vice President, Global Business Development, Simcere Pharmaceutical Group Kimberly Ha, Senior Director Strategic Communications, FTI Consulting Mark Tang, Managing Director, Good Health Capital Brianne Weingarten, Head of Alliance Management, Licensing & Business Development, Purdue Pharma L.P.
5:00 PM – 6:30 PM	Networking Reception

September 29, 2016
7:45 AM	Breakfast – The Pechet Room
8:45 AM – 9:55 AM	GLOBALIZATION OF THE ASIAN INDUSTRY – How North American biopharma companies can attract Asian innovation through outward and/or inward partnerships and investments Larry Cai, Head of Business Development, New England, Qilu Pharmaceuticals Chris Francis, PhD, Senior Vice President, Corporate Development & Portfolio Management, WAVE Life Sciences Julia P. Gregory, Former CEO, ContraFect Corporation Derrick Li, Director, Investing and Licensing, North America, TPP Healthcare Tim Opler, PhD, Partner, Torreya Partners
9:55 AM – 10:10 AM	Break
10:10 AM – 11:05 AM	DUE DILIGENCE AND DEAL MAKING IN ASIA – What you need to know to avoid pitfalls and ensure an effective deal Linda M. Pullan, PhD, Founder, Pullan Consulting Jeff Tomlinson, CBO, ASLAN Pharmaceuticals Xiaoming Zou, PhD, CEO, EOC Pharma
11:10 AM – 12:05 PM	THE COMPLEXITIES OF REGULATORY REGIMES – Understanding and navigating the various regulatory regimes in Asia RuiPing Dong, Managing Director, RuiPing Consulting Jurij Petrin, MD, President and Chief Executive Officer, Pharmaceutical Regulatory Services, Inc. Bill Pignato, Founder and Principal, W.J. Pignato & Associates, LLC
12:10 PM– 1:20 PM	Lunch with the Experts
1:25 PM – 2:20 PM	MANAGING INTELLECTUAL PROPERTY IN ASIA – The challenges and opportunities for biotech companies, including retaining US commercialization rights in license deals Judy Jarecki-Black, PhD, Head, IP, Merial Grace L. Pan, Partner, Holland & Knight LLP Fang Xie, PhD, Co-Leader, Biotechnology & Pharmaceutical Industry Group, Greenberg Traurig, LLP
2:25 PM – 3:30 PM	THE VIEW FROM BIG PHARMA – How does Big Pharma view the role of Trans-Pacific Partnerships? Yuan-Hua Ding, Executive Director and Head of Pfizer External R&D Innovation (ERDI) – Asia/Pacific, Pfizer Worldwide Research & Development Julia P. Gregory, Former CEO, ContraFect Corporation James B. Weissman, CBO, Dicerna Pharmaceuticals Wei Zhang, Investor, Lilly Asia Ventures
3:30 PM – 4:30 PM	Closing Reception